Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview
Future Prospects in the Sequencing Market
Chapter 2: Introduction
Overview – Next Generation Sequencing Market Is Rapidly Changing
History of DNA Sequencing
Point-of-View
Chapter 3: Sequencing Technology
Sanger Sequencing
Next-Generation Sequencing
Massively Parallel Signature Sequencing (MPSS)
Pyrosequencing
454 Technology
Sequencing by Synthesis (SBS)
Supported Oligonucleotide Ligation and Detection (SOLiD)
Ion Torrent Sequencing
Single Molecule Real Time (SMRT) Sequencing
DNA Nano Ball Sequencing
Nanopore Sequencing
Other Sequencing Technologies
Sequencing Applications/Types of Sequencing
Sample or Library Preparation
Information Technology
Sample-to-Answer (Sample-to-Insight) Workflows or Platforms
Rapid Next Generation Sequencing Testing
Chapter 4: Sequencing Applications
Research, Drug Discovery and Development
Clinical Diagnostic Applications of Sequencing
Cancer Diagnostics: NGS Based Tests for Oncology
Cancer Diagnostics: Liquid Biopsies
Genetic Analysis – Inherited Disorders, Prenatal and Postnatal Diagnostics
Infectious Disease Diagnostics
Human Leukocyte Antigen (HLA) Testing
Other Diagnostic Applications of Sequencing
Direct-to-Consumer Genetic Testing Industry
Chapter 5: Deals – Next Generation Sequencing Companies
Investments and Financing Agreements
Mergers and Acquisitions
Other Corporate Agreements and Collaborations
Collaborations/Agreements with Diagnostic Companies and/or Clinical Laboratories
Collaborations/Agreements with Pharmaceutical and Biopharmaceutical Companies
Collaborations/Agreements between Two Companies in Next Generation Sequencing
Other Company Collaborations/Agreements
Collaborations and Other Agreements with Universities, Non-Profit Research Institutes and Government
Chapter 6: Applying Sequencing to Diagnostics – Market Drivers and Challenges
Overcoming Technology Hurdles – Sample Preparation and Data Analysis
Advances in Next Generation Sequencing Platforms
Next Generation Sequencing Market Drivers
Advances in Technology
Research Market Drivers
Increasing Number of Clinical Applications for Next Generation Sequencing
Cancer Diagnostic Market Drivers
Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics] Market Drivers
Infectious Disease Diagnostic Market Drivers
Market Drivers for Other Segments of the Diagnostic Market
Issues and Hurdles Faced by NGS Companies Selling to the Research Market
Issues and Hurdles Faced by Clinical Laboratories Doing NGS
Regulation of Next Generation Sequencing-Based In Vitro Diagnostic (IVD) Tests
Regulation of Companion Diagnostics
Complexities of Companion Diagnostic Tests and Corresponding Therapeutic Products; Harmonization of Companion Diagnostic Tests Across a Class of Targeted Therapies
Cost and Reimbursement Issues
Competition
Future Prospects
Chapter 7: Sequencing Market Analysis
Sequencing Market Overview
Sequencing Market – Geographical Distribution
Brand Ownership
Sequencing Market – Research versus Clinical Use
Sequencing Methods/Applications
Clinical Sequencing Market – Disease Indications
Analysis of Deals Activity in Next Generation Sequencing
Chapter 8: Company Profiles – Next Generation Sequencing Companies
10x Genomics, Inc.
23andMe, Inc.
Abbott Laboratories
Recent Revenue History
Company Overview – With a Focus on Sequencing
ACT Genomics Co., Ltd.
Adaptive Biotechnologies Corporation
Admera Health
Advanced Biological Laboratories (ABL), S.A
Agilent Technologies Inc.
Recent Revenue History
Company Overview
AltheaDx, Inc.
Ambry Genetics Corp.
Aperiomics, Inc.
Asuragen, Inc.
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
Base4 Innovation Ltd
Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
Revenue History
Company Overview
Becton, Dickinson and Company (BD)
Recent Revenue History
Company Overview
BGI
Bina Technologies, Inc. (Part of Roche Sequencing)
BioDiscovery, Inc.
Biomatters Ltd.
bioMérieux SA
Recent Revenue History
Company Overview
bioTheranostics, Inc.
Cancer Genetics, Inc.
Recent Revenue History
Company Overview
CareDx, Inc.
Recent Revenue History
Company Overview
Caris Life Sciences
CLC bio (A QIAGEN Company)
Color Genomics, Inc.
Complete Genomics (A BGI Company)
Courtagen Life Sciences, Inc.
Cynvenio Biosystems, Inc.
DNA Electronics Ltd.
Eurofins Genomics
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
Recent Revenue History
Company Overview
GATC Biotech AG
GenapSys, Inc.
GenDx
GENEWIZ Inc.
Genia Technologies, Inc. (Part of Roche Sequencing)
Genomic Health, Inc.
Recent Revenue History
Company Overview
Genoptix (A Novartis Company)
GnuBIO, Inc. (A Bio-Rad Company)
GRAIL
Guardant Health, Inc.
Helix
HTG Molecular Diagnostics
Recent Revenue History
Company Overview
Human Longevity, Inc.
Illumina, Inc.
Recent Revenue History
Company Overview
Inivata Ltd.
Invitae Corporation
Recent Revenue History
Company Overview
Invivoscribe Technologies, Inc.
Laboratory Corporation of America (LabCorp)
Recent Revenue History
Company Overview
Lasergen, Inc.
MolecularMD Corporation
Myriad Genetics, Inc.
Recent Revenue History
Company Overview
NANTOMICS (Member of the NantWorks ecosystem of companies)
Natera, Inc.
NeoGenomics, Inc./NeoGenomics Laboratories
Recent Revenue History
Company Overview
N-of-One, Inc.
OncoDNA SA
Oncospire Genomics
Oxford Nanopore Technologies Ltd.
Pacific Biosciences of California, Inc.
Recent Revenue History
Company Overview
Pathway Genomics Corporation
Personal Genome Diagnostics, Inc.
Personalis, Inc.
QIAGEN N.V.
Recent Revenue History
Company Overview
Quest Diagnostics
Recent Revenue History
Company Overview
RainDance Technologies, Inc.
Roche
Recent Revenue History
Company Overview
Siemens Healthcare Diagnostics
Recent Revenue History
Company Overview
Stratos Genomics Inc.
Sysmex Corporation
Recent Revenue History
Company Overview
Thermo Fisher Scientific, Inc.
Recent Revenue History
Company Overview
List of Exhibits
1: Executive Summary
Table 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2015 and 2020
3: Sequencing Technology
Table 3-1: Current and Emerging Sequencing Technologies and Platforms
Table 3-2: Selected Companies Developing/Marketing Products for NGS Sample or Library Preparation
Table 3-3: Selected Companies Developing/Marketing NGS Information Technology Solutions
Table 3-4: Selected Companies Developing NGS Sample-to-Answer(Sample-to-Insight) Platforms
Table 3-5: Selected Companies Developing Rapid NGS Assays or Platforms
4: Sequencing Applications
Table 4-1: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
Table 4-2: Selected Companies Developing and/or Marketing Liquid Biopsy Assays
Table 4-3: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis [Inherited Disorders,Prenatal and Postnatal Diagnostics]
Table 4-4: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
Table 4-5: Selected Companies Offering Products/Services for Applications of DNA Sequencing in Human Leukocyte Antigen (HLA) Testing
Table 4-6: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications
5: Deals – Next Generation Sequencing Companies
Table 5-1: Selected Investment and Financing Agreements in Next Generation Sequencing Companies [Includes IT Companies in NGS]
Table 5-2: Selected Acquisitions of Next Generation Sequencing Companies[Includes IT Companies in NGS]
Table 5-3: Selected Agreements between Next Generation Sequencing Companies and Diagnostic Companies or Clinical Laboratories [Includes IT Companies in NGS]
Table 5-4: Examples of Diagnostic Companies and Clinical Laboratories That Have Made Agreements in Next Generation Sequencing
Table 5-5: Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies [Includes Contract Research Organizations Providing Services to Pharma Companies]
Table 5-6: Selected Pharmaceutical and Biopharmaceutical Companies Using or Active in Next Generation Sequencing
Table 5-7: Selected Company Agreements between Two Next Generation Sequencing Companies [Includes IT Companies in NGS]
Table 5-8: Selected Other Next-Generation Sequencing Company Agreements in Next Generation Sequencing [Includes IT Companies in NGS]
Table 5-9: Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations [Includes IT Companies in NGS]
7: Sequencing Market Analysis
Table 7-1: Sequencing Market, Worldwide, 2015 and 2020 (Instrument Revenue, Consumables Revenue, Services Revenue, Total Market)
Table 7-2: Sequencing Market by Geographical Region, Worldwide, 2015 and 2020 (North America, Europe, Asia, Rest of World, Total Market)
Figure 7-2: Next Generation Sequencing System Ownership by Country, Percentage (United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia, Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
Figure 7-3: Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
Figure 7-5: Research Sequencing Market – Types of Sequencing: Targeted or Whole Exome Sequencing versus de novo or Whole Genome Sequencing (2015)
Figure 7-6: Clinical Sequencing Market by Disease Category, 2015, Percentage (Genetic Testing/Inherited Disorders, Other Disorders)
Figure 7-7: Clinical Sequencing Market by Disease Category, 2020, Percentage(Oncology, Genetic Testing/Inherited Disorders, Infectious Disease, Other Disorders)
Table 7-3: Investments in Next Generation Sequencing Companies, 2015 and First Half of 2016
8: Company Profiles – Next Generation Sequencing Companies
Table 8-1: Abbott Revenues (2013, 2014, 2015)
Table 8-2: Agilent Technologies Revenues (2013, 2014, 2015)
Table 8-3: Becton, Dickinson and Company (BD) Revenues (2013, 2014, 2015)
Table 8-4: bioMérieux Revenues (2013, 2014, 2015)
Table 8-5: bioMérieux Revenues (2014 and 2015) – By Region, and by Technology and Application
Table 8-6: Cancer Genetics Revenues (2013, 2014, 2015)
Table 8-7: CareDx Revenues (2013, 2014, 2015)
Table 8-8: Foundation Medicine Revenues (2013, 2014, 2015)
Table 8-9: Genomic Health Revenues (2013, 2014, 2015)
Table 8-10: HTG Molecular Diagnostics (2014 and 2015)
Table 8-11: Illumina (2013, 2014, 2015)
Table 8-12: Invitae Corporation Revenues (2013, 2014, 2015)
Table 8-13: Laboratory Corporation of America (LabCorp) Revenues (2013,2014, 2015)
Table 8-14: Myriad Genetics Revenues (2013, 2014, 2015)
Table 8-15: NeoGenomics Revenues (2013, 2014, 2015)
Table 8-16: Pacific Biosciences Revenues (2013, 2014, 2015)
Table 8-17: QIAGEN Revenues (2013, 2014, 2015)
Table 8-18: QIAGEN – Distribution of Sales in 2015
Table 8-19: Quest Diagnostics Revenues (2013, 2014, 2015)
Table 8-20: Roche Revenues (2014 and 2015)
Table 8-21: Siemens Revenues (2014 and 2015)
Table 8-22: Sysmex Revenues (2013, 2014, 2015)
Table 8-23: Thermo Fisher Scientific Revenues (2013, 2014, 2015)
